JP2014525584A - 癌の治療および診断のための方法および組成物 - Google Patents

癌の治療および診断のための方法および組成物 Download PDF

Info

Publication number
JP2014525584A
JP2014525584A JP2014528663A JP2014528663A JP2014525584A JP 2014525584 A JP2014525584 A JP 2014525584A JP 2014528663 A JP2014528663 A JP 2014528663A JP 2014528663 A JP2014528663 A JP 2014528663A JP 2014525584 A JP2014525584 A JP 2014525584A
Authority
JP
Japan
Prior art keywords
homosapiens
homo sapiens
protein
family
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014528663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525584A5 (enExample
Inventor
チャップマン，カレン
ワーグナー，ジョセフ
ウェスト，マイケル
キッド，ジェニファー，ローリー
プレンディズ，マリア
ラッハー，マーカス
Original Assignee
オンコサイト コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコサイト コーポレーション filed Critical オンコサイト コーポレーション
Publication of JP2014525584A publication Critical patent/JP2014525584A/ja
Publication of JP2014525584A5 publication Critical patent/JP2014525584A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2014528663A 2011-08-31 2012-08-31 癌の治療および診断のための方法および組成物 Pending JP2014525584A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161529500P 2011-08-31 2011-08-31
US61/529,500 2011-08-31
US201161542403P 2011-10-03 2011-10-03
US61/542,403 2011-10-03
PCT/US2012/053472 WO2013033609A2 (en) 2011-08-31 2012-08-31 Methods and compositions for the treatment and diagnosis of cancer

Publications (2)

Publication Number Publication Date
JP2014525584A true JP2014525584A (ja) 2014-09-29
JP2014525584A5 JP2014525584A5 (enExample) 2015-10-29

Family

ID=47757190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528663A Pending JP2014525584A (ja) 2011-08-31 2012-08-31 癌の治療および診断のための方法および組成物

Country Status (9)

Country Link
US (1) US20140206574A1 (enExample)
EP (1) EP2751570A4 (enExample)
JP (1) JP2014525584A (enExample)
KR (1) KR20140057361A (enExample)
CN (1) CN103890587A (enExample)
AU (1) AU2012301664A1 (enExample)
CA (1) CA2844793A1 (enExample)
HK (1) HK1199099A1 (enExample)
WO (1) WO2013033609A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016140262A (ja) * 2015-01-30 2016-08-08 国立大学法人山口大学 肝細胞がんの転移性再発リスクの予測方法
WO2016143697A1 (ja) * 2015-03-06 2016-09-15 国立大学法人名古屋大学 Ｓｙｔ１３、ｓｙｔ８、ａｎｏｓ１発現量による胃癌腹膜播種の検査方法、検査キット、分子標的治療薬スクリーニング方法、及び治療薬
JP2017009381A (ja) * 2015-06-19 2017-01-12 国立大学法人滋賀医科大学 癌の検査方法、癌細胞増殖阻害剤、抗癌剤及び抗癌剤のスクリーニング方法
JP2019510506A (ja) * 2015-12-31 2019-04-18 ルー メイソン 抗ポドカリキシン様タンパク質前駆体サブタイプ２モノクローナル抗体とその生成方法及び使用
JP2019514365A (ja) * 2016-04-20 2019-06-06 ヒロプローブ・エービー 大腸癌の分類のためのマーカー遺伝子、大腸癌の予後診断におけるリンパ節転移の決定のための方法及びそのためのキット
JP2020091175A (ja) * 2018-12-05 2020-06-11 学校法人関西医科大学 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー
JP2021003136A (ja) * 2015-05-15 2021-01-14 国立大学法人高知大学 膵がん診断キット
JP2021533731A (ja) * 2018-05-29 2021-12-09 トゥルン イリオピスト 結腸がんの予測バイオマーカーとしてのｌ１ｔｄ１

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160080A1 (en) 2008-05-14 2011-06-30 Chang Sherman H Diagnosis of Melanoma and Solar Lentigo by Nucleic Acid Analysis
WO2014055398A1 (en) 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
EP2853596A1 (en) * 2013-09-30 2015-04-01 IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) Protein phosphatase inhibitor
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
EP2876442A1 (en) 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
WO2015103166A1 (en) * 2013-12-30 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
WO2016179043A1 (en) 2015-05-01 2016-11-10 Dermtech, Inc. Non-invasive skin collection system
AU2015277059B2 (en) * 2014-06-18 2021-06-17 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
KR101779147B1 (ko) * 2014-07-04 2017-09-20 연세대학교 산학협력단 Kiaa1199를 이용한 췌장암의 진단 또는 치료용 조성물
CN105675735B (zh) * 2014-11-19 2018-07-17 上海市第六人民医院 乳腺癌诊断标记物组合、应用及其测定方法
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
CR20210232A (es) 2015-03-17 2022-06-24 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
CN105463070B (zh) * 2015-07-08 2018-12-28 上海市同仁医院 Uca1基因在制备诊断结直肠癌产品中的应用
US10370647B2 (en) * 2015-07-22 2019-08-06 National University Corporation Tottori University Host regulatory factor that enhances replication and/or propagation of vaccinia virus
US20190316204A1 (en) * 2015-07-24 2019-10-17 Korea University Research And Business Foundation Biomarker for determining aging, determining obesity, and diagnosing cancer and diagnosing kit using same
US20170089905A1 (en) * 2015-09-28 2017-03-30 Abbott Japan Co., Ltd. Methods of diagnosing hepatocellular carcinoma and pancreatic cancer
ES2902477T3 (es) * 2015-12-04 2022-03-28 Univ Texas Péptidos SLC45A2 para inmunoterapia
WO2017113565A1 (zh) * 2015-12-29 2017-07-06 中国医学科学院肿瘤医院 基于蛋白标志物psg3辅助诊断肝癌或消化道癌症患者的试剂盒
US10294297B2 (en) 2016-01-29 2019-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment using anti-NMU agents
CN106399306B (zh) * 2016-04-12 2019-11-05 西安交通大学第一附属医院 靶向人lncRNA-UCA1抑制膀胱癌的sgRNA、基因载体及其应用
CN106047874B (zh) * 2016-06-02 2019-01-18 吉林大学 一种靶向sall4基因的脱氧核酶分子及在乳腺癌基因治疗中的应用
EP3468546A4 (en) 2016-06-09 2020-04-01 Cedars-Sinai Medical Center COMPOSITIONS AND METHODS FOR TREATING CANCER
CN108329387B (zh) * 2017-01-17 2021-07-27 复旦大学附属肿瘤医院 癌症相关的肿瘤特异转录本lin28b-tst及其用途
CN110869518A (zh) * 2017-05-16 2020-03-06 香港中文大学 整合式单细胞和游离血浆rna分析
WO2018218737A1 (zh) * 2017-06-01 2018-12-06 立森印迹诊断技术（无锡）有限公司 一种印记基因在膀胱肿瘤中的分级模型及其组成的系统
CN107312096B (zh) * 2017-07-17 2019-12-20 湖北大学 用于检测组蛋白位点三甲基化修饰的重组蛋白及其应用
CN107449916B (zh) * 2017-07-27 2019-05-21 北京邦菲生物科技有限公司 肺癌和肺部结节蛋白特征谱及其构建方法与应用
CN108152496B (zh) * 2017-11-24 2020-10-27 暨南大学 Mest蛋白在制备肺癌辅助诊断和/或预后判断的试剂盒中的应用
CN107807243B (zh) * 2017-11-24 2020-08-07 暨南大学 一种食管癌的生物标志物及其应用
EP3724217A4 (en) * 2017-12-13 2022-01-12 Inovio Pharmaceuticals, Inc. LEMD1-TARGETING CANCER VACCINES AND THEIR USES
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
GB201803750D0 (en) * 2018-03-08 2018-04-25 Immunocore Ltd Method
CN108796079B (zh) * 2018-06-06 2021-07-27 天津医科大学肿瘤医院 一种逆转录转座基因l1-fggy及其作为肺鳞癌标志物的用途
CN109116023B (zh) * 2018-06-14 2021-06-04 郑州大学第一附属医院 一种肺癌标志物抗-mmp12自身抗体及其应用
WO2019241899A1 (es) * 2018-06-20 2019-12-26 Pontificia Universidad Catolica De Chile Detección no invasiva de cáncer gástrico a través de la detección en sangre de la metilación de reprimo like
US20210275596A1 (en) * 2018-07-20 2021-09-09 Cell2In, Inc. Application of gene profile for cells isolated using fresh-tracer
CN109082473A (zh) * 2018-10-16 2018-12-25 兰州大学 一种公牛znf280ay基因拷贝数变异的检测方法及应用
WO2020080861A1 (ko) 2018-10-19 2020-04-23 한국생명공학연구원 Syt11 억제제를 유효성분으로 포함하는 위암 치료용 조성물
CN109371023A (zh) * 2018-12-11 2019-02-22 宁夏医科大学总医院 一种环状RNA hsa_circKIAA1199_006及其特异性扩增引物和应用
CA3134936A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
AU2020266560A1 (en) 2019-04-30 2021-11-25 Absci Corporation Cancer associated antibody compositions and methods of use
CN110218796B (zh) * 2019-06-27 2020-01-17 江门市中心医院 用于乳腺癌骨转移诊疗的新靶标pcdhb2
CN112147324A (zh) * 2019-06-28 2020-12-29 欧蒙医学实验诊断股份公司 自身抗体的检测
US20220357329A1 (en) * 2019-07-01 2022-11-10 Accure Health Inc. Predictive liquid markers for cancer immunotherapy
US12613245B2 (en) 2019-10-15 2026-04-28 Cornell University Methods for detecting and inhibiting brain metastasis
CN110796625B (zh) * 2019-10-30 2023-06-20 重庆邮电大学 一种基于组稀疏表示和加权全变分的图像压缩感知重构方法
CN111218509B (zh) * 2019-12-23 2023-07-04 西南医科大学附属医院 乳腺癌的新诊断标志物ppef1及其应用
US20230348592A1 (en) * 2020-05-12 2023-11-02 Memorial Sloan Kettering Cancer Center Methods for de-cloaking cancer from the immune system through downregulation of cancer-produced pregnancy specific glycoprotein
WO2022140565A1 (en) * 2020-12-22 2022-06-30 Nutech Ventures Methods and materials for assessing radiation exposure
CN115851942A (zh) * 2020-12-22 2023-03-28 上海市第一人民医院 诊断标志物gata4在胰腺“炎癌转化”中的应用
CN115216542A (zh) * 2021-04-15 2022-10-21 复旦大学附属华山医院 一组肿瘤筛查、鉴别的标志物及应用
CN116087519B (zh) * 2021-05-17 2025-03-14 郑州大学第一附属医院 一种用于高危人群贲门腺癌早期筛查的标志物及其应用
CN113504370B (zh) * 2021-06-29 2024-02-09 广州金研生物医药研究院有限公司 Mapk15蛋白在前列腺癌的恶性程度或预后程度预测中的应用
CN115537464B (zh) * 2021-06-30 2023-06-20 武汉艾米森生命科技有限公司 一种结直肠癌或癌前病变的诊断或辅助诊断试剂、核酸组合、试剂盒及应用
CN113980963B (zh) * 2021-09-03 2024-05-28 中山大学 一种寡核苷酸rna双链分子及其在制备治疗恶性肿瘤药物中的应用
CN114807369A (zh) * 2021-11-15 2022-07-29 四川大学华西医院 一种与前列腺癌显著相关的潜在抗原、免疫分型及其构建方法和应用
CN115992229B (zh) * 2022-07-22 2023-07-07 中南大学湘雅三医院 一种胰腺癌预后风险评估的lncRNA标记物、模型及其应用
CN115960253A (zh) * 2022-08-30 2023-04-14 暨南大学 一种肿瘤T细胞抗原表位肽、pMHC及其制备和应用
CN115838804A (zh) * 2022-10-07 2023-03-24 厦门医学院 血浆外泌体lncRNAs作为靶标在急性髓系白血病诊断和疗效监测中的应用
CN115786518A (zh) * 2022-11-29 2023-03-14 广东医科大学附属医院 嗅素结构域家族蛋白4（olfm4）在结肠癌检测产品中的应用
CN116042808A (zh) * 2022-12-07 2023-05-02 浙江大学医学院附属妇产科医院 Gngt1在aub-m诊断中的应用
CN116482365B (zh) * 2023-03-14 2023-10-20 南京芯原生物科技有限公司 用于检测血清抗体的蛋白组合物及其应用
WO2026054347A1 (ko) * 2024-09-04 2026-03-12 사회복지법인 삼성생명공익재단 폐암 진단용 바이오마커 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009540803A (ja) * 2006-06-23 2009-11-26 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
WO2010046530A1 (en) * 2008-10-20 2010-04-29 Helsingin Yliopiston Rahastot Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155282A0 (en) * 2000-10-18 2003-11-23 Glaxosmithkline Biolog Sa Vaccines
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2005532036A (ja) * 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
CA3061769C (en) * 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
US20050208499A1 (en) * 2004-02-04 2005-09-22 Graff Jonathan M Markers for diagnosing and treating breast and ovarian cancer
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
EP1904657B1 (en) * 2005-06-08 2011-05-25 Hitachi Chemical Research Center, Inc. METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
US20070218512A1 (en) * 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
DE102006024416A1 (de) * 2006-05-24 2008-04-30 Friedrich-Alexander-Universität Erlangen-Nürnberg Prädiktives Genexpressionsmuster für kolorektale Karzinome
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
AT504702A1 (de) * 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
US20100087330A1 (en) * 2007-01-26 2010-04-08 Brian Leyland-Jones Breast cancer gene array
EP2048242A1 (de) * 2007-10-08 2009-04-15 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Microarray für die Expressionsanalyse der zellulären Glykosylierungsmaschinerie
EP2215261B1 (en) * 2007-10-23 2018-02-21 Clinical Genomics Pty Ltd A method of diagnosing neoplasms
JP2011521215A (ja) * 2008-05-14 2011-07-21 エーテーハー チューリヒ 前立腺癌の診断及び治療のためのバイオマーカー及び薬剤標的発見法、並びにそれを用いて決定されるバイオマーカーアッセイ
US8945849B2 (en) * 2008-05-21 2015-02-03 Toray Industries, Inc. Method for diagnosing esophageal cancer
EP3831954A3 (en) * 2008-11-17 2021-10-13 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
CN102348979A (zh) * 2009-03-09 2012-02-08 乔治亚大学研究基金公司 胃癌诊断用蛋白标记的鉴定
BR112012002942A2 (pt) * 2009-08-10 2015-10-13 Epitherix Llc indazóis como inibidores da trilha de sinalização de wnt/b-catenina e empregos terapêuticos destes.
AU2011221226A1 (en) * 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009540803A (ja) * 2006-06-23 2009-11-26 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
WO2010046530A1 (en) * 2008-10-20 2010-04-29 Helsingin Yliopiston Rahastot Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016140262A (ja) * 2015-01-30 2016-08-08 国立大学法人山口大学 肝細胞がんの転移性再発リスクの予測方法
WO2016143697A1 (ja) * 2015-03-06 2016-09-15 国立大学法人名古屋大学 Ｓｙｔ１３、ｓｙｔ８、ａｎｏｓ１発現量による胃癌腹膜播種の検査方法、検査キット、分子標的治療薬スクリーニング方法、及び治療薬
JPWO2016143697A1 (ja) * 2015-03-06 2017-12-28 国立大学法人名古屋大学 Ｓｙｔ１３、ｓｙｔ８、ａｎｏｓ１発現量による胃癌腹膜播種の検査方法、検査キット、分子標的治療薬スクリーニング方法、及び治療薬
JP2021003136A (ja) * 2015-05-15 2021-01-14 国立大学法人高知大学 膵がん診断キット
JP7085235B2 (ja) 2015-05-15 2022-06-16 国立大学法人高知大学 膵がん診断キット
JP2017009381A (ja) * 2015-06-19 2017-01-12 国立大学法人滋賀医科大学 癌の検査方法、癌細胞増殖阻害剤、抗癌剤及び抗癌剤のスクリーニング方法
JP2019510506A (ja) * 2015-12-31 2019-04-18 ルー メイソン 抗ポドカリキシン様タンパク質前駆体サブタイプ２モノクローナル抗体とその生成方法及び使用
JP2019514365A (ja) * 2016-04-20 2019-06-06 ヒロプローブ・エービー 大腸癌の分類のためのマーカー遺伝子、大腸癌の予後診断におけるリンパ節転移の決定のための方法及びそのためのキット
JP2021533731A (ja) * 2018-05-29 2021-12-09 トゥルン イリオピスト 結腸がんの予測バイオマーカーとしてのｌ１ｔｄ１
JP2020091175A (ja) * 2018-12-05 2020-06-11 学校法人関西医科大学 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー
JP7216995B2 (ja) 2018-12-05 2023-02-02 学校法人関西医科大学 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー

Also Published As

Publication number Publication date
CA2844793A1 (en) 2013-03-07
WO2013033609A2 (en) 2013-03-07
AU2012301664A1 (en) 2014-02-27
EP2751570A4 (en) 2015-08-12
WO2013033609A3 (en) 2013-06-27
US20140206574A1 (en) 2014-07-24
KR20140057361A (ko) 2014-05-12
EP2751570A2 (en) 2014-07-09
HK1199099A1 (en) 2015-06-19
CN103890587A (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
US20140206574A1 (en) Methods and Compositons for the Treatment and Diagnosis of Cancer
CN103975078B (zh) 治疗和诊断膀胱癌的方法和组合物
AU2012296405B2 (en) Methods and compositions for the treatment and diagnosis of breast cancer
US20140221244A1 (en) Methods and Compositions for the Treatment and Diagnosis of Colorectal Cancer
US20150018235A1 (en) Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
JP2011217749A (ja) 疾患に対する体液性応答のファージ・マイクロアレイ・プロファイリング法
US20140141996A1 (en) Methods and Compositions for the Treatment and Diagnosis of Cancer
CA2840472A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
US20140357518A1 (en) Methods and Compositions for the Treatment and Diagnosis of Thyroid Cancer
US20140315743A1 (en) Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
KR102216590B1 (ko) 췌장 신경내분비종양의 진단을 위한 조성물
WO2017181163A2 (en) Methods and compositions for detection and diagnosis of breast cancer
WO2015013455A2 (en) Methods and compositions for the treatment and diagnosis of cancer
US20130295581A1 (en) Methods and Compositions for the Treatment and Diagnosis of Breast Cancer
WO2017214189A1 (en) Methods and compositions for detection and diagnosis of bladder cancer
WO2011029193A1 (en) Method of treating cancer by inhibiting trim59 expression or activity
WO2024227553A1 (en) Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
WO2019074920A1 (en) METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150831

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170307